ID

34430

Descripción

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661

Link

https://clinicaltrials.gov/show/NCT02468661

Palabras clave

  1. 17/1/19 17/1/19 -
  2. 20/4/20 20/4/20 -
  3. 25/4/20 25/4/20 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

17 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Non-Small Cell Lung Cancer NCT02468661

Eligibility Non-Small Cell Lung Cancer NCT02468661

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
locally advanced or metastatic nsclc
Descripción

ID.1

Tipo de datos

boolean

egfr mutation (l858r and /or ex19del)
Descripción

ID.2

Tipo de datos

boolean

cmet amplification by fish (gcn ≥ 6),
Descripción

ID.3

Tipo de datos

boolean

acquired resistance to egfr tki (1st or 2nd génération)
Descripción

ID.4

Tipo de datos

boolean

ecog performance status (ps) ≤ 1.
Descripción

ID.5

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with 3rd generation tki
Descripción

ID.6

Tipo de datos

boolean

phaseii : prior treatment with any of the following agents:
Descripción

ID.7

Tipo de datos

boolean

crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
Descripción

ID.8

Tipo de datos

boolean

concomitant egfr tki and platinum based chemotherapy as first line regimen.
Descripción

ID.9

Tipo de datos

boolean

platinum-based chemotherapy as first line treatment
Descripción

ID.10

Tipo de datos

boolean

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02468661

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
locally advanced or metastatic nsclc
boolean
ID.2
Item
egfr mutation (l858r and /or ex19del)
boolean
ID.3
Item
cmet amplification by fish (gcn ≥ 6),
boolean
ID.4
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
ID.5
Item
ecog performance status (ps) ≤ 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with 3rd generation tki
boolean
ID.7
Item
phaseii : prior treatment with any of the following agents:
boolean
ID.8
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
ID.9
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
ID.10
Item
platinum-based chemotherapy as first line treatment
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial